期刊文献+

氟尿嘧啶治疗结直肠癌的临床护理分析

下载PDF
导出
摘要 目的本次实验将针对结直肠癌患者采用氟尿嘧啶进行治疗,并探究临床护理的有效性。方法本次实验选取了2017年1月-2017年12月在我院就诊的结直肠癌患者为讨论的对象,入选的患者共36例,均采用氟尿嘧啶进行治疗,对照组采用常规的护理模式,观察组则加强护理关注,帮助患者完成化疗过程,改善不良反应。结果观察组患者的临床护理有效率更高,为94.4%,优于对照组的77.8%,组间对比差异较为显著,具有统计学意义(P<0.05)。与此同时,在神经系统异常、口腔黏膜问题上较少,组间对比差异显著,故而观察组的护理质量更佳。结论采用氟尿嘧啶治疗结直肠癌具有良好的改善效果,在临床护理的协助下,患者病情改善情况良好,治疗结果得到了保障。
出处 《结直肠肛门外科》 2018年第A02期256-257,共2页 Journal of Colorectal & Anal Surgery
  • 相关文献

参考文献2

二级参考文献15

  • 1孙燕,石远凯.临床肿瘤内科手册[M].第5版.北京:人民卫生出版社,2010:770.
  • 2Carter HE, Zannino D, John Simes R, et al. The cost effectiveness ofbevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: results from the Australasian phase III MAX study[J]. Eur J Cancer,2014,50(3) :535.
  • 3Cassidy J, Douillard JY, Twelves C, et al. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial[J]. Br J Cancer,2006,94(8):1122.
  • 4Cassata A, Procoplo G, Alu M, et al. Capecitabine: indications and fu- ture perspectives in the treatment of metastatic colorectal and breast can- cer[J]. Tumori,2001,87(6) :364.
  • 5Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine com- pared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer:results of a large phase III study[J]. J Clin Oncol,2001,19(21) :4097.
  • 6Hoff PM, Ansari R, Batist G, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study[J]. J Clin Oncol, 2001,19(8):2282.
  • 7Delea TE, Vera-Llonch M, Edelsberg JS, et al. The incidence and cost of hospitalization for 5-FU toxicity among Medicare beneficiaries with metastatic colorectal cancer[J]. Value Health ,2002,5(1):35.
  • 8Cassidy J, Clarke S, Diaz-Rubio E, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer[ J]. J Clin Oncol, 2008,26(12) : 2006.
  • 9Cassidy J, Rotherd)erg M, Saltz L, et al. Meta-analysis of overall sur- vival in 6 randomised phase HI clinical trials of capecitabine vs. 5-FU in colorectal and gastric cancer. Presented at the lOth World Congress on Gastrointestinal Cancer, June 25-28, 2008[ C]. Barcelona, Spain, 2008.
  • 10Eggington S, Tappenden P, Pandor A, et al. Cost-effectiveness of ox- aliplatin and capecitabine in the adjuvant treatment of stage i11 colon cancer[J]. Br J Cancer, 2006,95(9) : 1195.

共引文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部